Notice: Passwords are now case-sensitive

Remember Me
Register a new account
Forgot your password?

Paduda: Implications Abound in Mitchell's Coventry Acquisition

By Joe Paduda

Wednesday, August 5, 2020 | 522 | 0 | min read

The implications of Mitchell’s acquisition of Coventry’s workers’ comp business are broad, from insight into the future of mergers and acquisitions in workers’ comp services to impact on competitors. Today we’ll dive into a few of the top-line implications.

Joe Paduda

Joe Paduda


The $850 million price was likely driven largely by the network’s profits and sustained position as the work comp preferred provider organization industry leader. The PPO is by far the biggest revenue and margin generator for Coventry Workers’ Comp. The transaction also represents yet another step in the rapid consolidation in the work comp services industry.

Mitchell now owns the No. 2 bill review application (by customer base), the largest medical management entity (Genex Coventry), the largest case management business (a mixed blessing these days) and the dominant network. If it holds onto both pharmacy benefits managers, it will gain the No. 3 position in that sector.

Mitchell is likely off the major acquisition field for a good while. It has to fix its PBM business; integrate Coventry; develop and implement a customer outreach that ideally will result in more stuff being bought by more customers; and ensure Coventry’s distributors (including bill review rivals Medata and Conduent) continue to offer Coventry’s network, all while dealing with COVID-19’s impact on work comp and auto claims.

The other big players left in this business are OptumWC (network, PBM, ancillary services), Paradigm (cat case services and management, case management, some network and ancillary businesses), and One Call. The next tier includes bill review/document management company Conduent; and physical medicine expert MedRisk and myMatrixx (No. 2 PBM). Both are Health Strategies Associates consulting clients.

I don’t see any of these entities scrambling to react to the deal; they’ve known about it for months, and outside of Optum and Conduent, any impact is tangential.


Coventry’s PPO is the industry leader, and has been for decades. It has the most market share, is rated highest by customers and its policy of demanding top billing in any state (primary network status) remains secure. Expect Genex to invest heavily in the PPO. This will secure its leadership position and hold off competition from newer entrants, primarily Optum.

Bill review

The market’s perception of Coventry’s bill review function indicates room for improvement. In a survey I conducted two years ago, BR buyers rated bill review entities' customer service. Shoot me a comment if you want a copy of the survey.

Conduent handles much of Coventry’s bill review; how Mitchell will address this is an interesting question.

If you’ve got additional questions, leave them in the comments section and I’ll do my best to get answers posted.

What does this mean for you?

Smart acquisition at a very good price makes Mitchell the leading entity in workers’ comp services. I wouldn’t worry too much about Mitchell gaining too much market power.

Joseph Paduda is co-owner of CompPharma, a consulting firm focused on improving pharmacy programs in workers’ compensation. This column is republished with his permission from his Managed Care Matters blog.


Related Articles